Welcome to our dedicated page for Quest Diagnostics SEC filings (Ticker: DGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Quest Diagnostics Incorporated (NYSE: DGX) files reports with the U.S. Securities and Exchange Commission that provide formal insight into its operations as a medical laboratories company focused on diagnostic testing and diagnostic information services. On this page, investors can review Quest Diagnostics’ SEC filings alongside AI-powered tools that help explain the content and context of these documents.
Quest Diagnostics uses current reports on Form 8-K to disclose material events such as quarterly financial results and investor presentations. For example, the company has filed 8-Ks to announce results for specific quarters and to furnish presentation materials used at the J.P. Morgan Healthcare Conference, covering topics such as strategy, performance and market developments. These filings give investors structured access to information that the company shares with the market.
In addition to 8-Ks, users can expect to find Quest Diagnostics’ periodic reports, including annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically contain detailed discussions of business segments, risk factors and financial condition. While these specific forms are not reproduced in the provided data, they are standard components of a public company’s SEC reporting and are accessible through this filings page.
The platform enhances these documents with AI-generated summaries that highlight key points, helping users navigate complex language and lengthy sections. For instance, AI tools can surface main themes from a 10-K, summarize quarterly performance from a 10-Q or clarify the significance of information furnished in an 8-K. Real-time updates from the SEC’s EDGAR system ensure that new filings appear promptly.
Investors interested in governance, capital allocation and executive communications can use this page to monitor Quest Diagnostics’ regulatory disclosures, while AI assistance streamlines the process of reviewing and interpreting the company’s filings.
WENTWORTH TIMOTHY C reported acquisition or exercise transactions in this Form 4 filing.
Quest Diagnostics director Timothy C. Wentworth received an award of 198 phantom stock units linked to Quest Diagnostics common stock. These units were credited on account of his elective deferral of director cash compensation under the company’s Amended and Restated Deferred Compensation Plan for Directors and will be payable in cash when his service as a director ends.
The Vanguard Group amended its Schedule 13G for Quest Diagnostics Inc. The filing states that, following an internal realignment described in the filing, The Vanguard Group reports 0 shares beneficially owned of Quest Diagnostics common stock and 0% of the class as of 03/13/2026. The amendment explains that certain subsidiaries and business divisions will report holdings separately in reliance on SEC Release No. 34-39538 (January 12, 1998). The amendment is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.
Quest Diagnostics announced that its board of directors has elected Timothy (Tim) Wentworth, former chief executive officer of Walgreens Boots Alliance, Evernorth Health Services and Express Scripts, as a director. Including Mr. Wentworth, the board now has eleven members.
The board also appointed him to the Compensation and Leadership Development Committee and the Quality and Compliance Committee and determined he qualifies as an independent director under New York Stock Exchange standards and the company’s governance guidelines. As part of standard non-employee director compensation, he received a prorated one-time restricted share unit grant valued at approximately $43,000.
Quest highlights Mr. Wentworth’s extensive leadership background running large healthcare and consumer-focused organizations, including guiding Express Scripts into a Fortune 25 company with more than $100 billion in revenues before its acquisition by Cigna, as well as senior roles at Mary Kay and PepsiCo. The company’s press release with additional background is furnished as an exhibit.
WENTWORTH TIMOTHY C reported acquisition or exercise transactions in this Form 4 filing.
Quest Diagnostics director Timothy C. Wentworth received an equity award of 215 shares of Common Stock in the form of restricted stock units. The grant was reported at a price of $0.00 per share as compensation, not a market purchase. Following this award, his directly owned position reported in this filing is 215 shares.
QUEST DIAGNOSTICS INC director Timothy C. Wentworth filed an initial statement of beneficial ownership on Form 3. This filing establishes his status as an insider of the company. The filing does not report any stock purchases, sales, option exercises, gifts, or other transactions.
Quest Diagnostics Executive Vice President & CFO Sam Samad reported two stock transactions involving the company’s common stock. On a performance stock award settlement, he acquired 13,947 shares at $204.86 per share, increasing his direct holdings to 40,988 shares.
On the same date, 7,720 shares were disposed of at $204.86 per share, delivered back to Quest Diagnostics solely to cover tax withholding obligations related to that performance share award, leaving him with 33,268 directly owned shares after the tax-related disposition.
Quest Diagnostics EVP Catherine T. Doherty reported multiple stock transactions involving company common shares. On March 4, 2026, she acquired 11,364 shares as a performance stock award at $204.86 per share, approved under Rule 16b-3(d).
On the same date, 5,806 shares were disposed of back to Quest Diagnostics solely to cover tax withholding obligations from that award at $204.86 per share. On March 5, 2026, she executed an open-market sale of 5,558 shares at an average price of $206.21 per share pursuant to a pre-established Rule 10b5-1 sales plan.
After these transactions, she directly owned 67,122 common shares. She also indirectly held 4,502 shares through company 401(k) and supplemental deferred compensation plans, with amounts based on plan account balances and the market price of Quest Diagnostics stock.
Quest Diagnostics senior executive Mark E. Delaney reported stock-based compensation activity involving company common stock. On March 4, 2026, he acquired 5,682 shares of Quest Diagnostics common stock at a value of $204.86 per share through the settlement of a performance stock award approved under Rule 16b-3(d).
On the same date, 2,326 shares of common stock were disposed of back to Quest Diagnostics solely to cover tax withholding obligations related to that award, as indicated in the footnotes. Following these transactions, Delaney directly owned 11,864 shares of Quest Diagnostics common stock.
Quest Diagnostics senior executive Michael E. Prevoznick reported several share movements in Quest Diagnostics Inc. common stock. On March 5, 2026, he completed an open-market sale of 3,878 shares at $206.21 per share under a pre-arranged Rule 10b5-1 sales plan, leaving him with 37,557 directly held shares after that trade.
On March 4, 2026, he received a grant or award of 7,232 shares at a reference price of $204.86 per share, issued in settlement of a performance stock award that had been approved under Rule 16b-3(d). Also on that date, 3,354 shares were disposed of back to Quest Diagnostics solely to cover tax withholding obligations from that award settlement.
Separately, the filing notes indirect ownership of 5,737 shares through the company’s 401(k) and Supplemental Deferred Compensation Plan, with these plan holdings accumulated periodically by the plan trustee.
Quest Diagnostics CEO and President J. E. Davis reported mixed equity transactions involving company stock. On a grant date of March 4, 2026, Davis acquired 51,652 shares of Quest Diagnostics common stock at a price of $204.86 per share, issued in settlement of a performance stock award approved under Rule 16b-3(d). In a related move, 26,414 shares of common stock were disposed of back to the issuer at $204.86 per share to cover tax withholding obligations from the settlement. After these transactions, Davis directly held 142,423 shares of Quest Diagnostics common stock.